BJD Editor's Choice

The authors of this study explain that secukinumab has demonstrated significant efficacy with a good safety profile through 1 year in the treatment of plaque psoriasis. They set out to determine the long-term (3-year) efficacy and safety of secukinumab in moderate-to-severe psoriasis. In total, 168 patients receiving secukinumab 300 mg on a fixed-interval schedule, and 172 receiving secukinumab 300 mg retreatment as needed entered this extension study. Secukinumab 300 mg fixed interval sustained high efficacy: at the end of year 3, the proportion of responders achieving ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90) was 63.8%, with 42.6% achieving PASI 100 response.

from # All Medicine by Alexandros G. Sfakianakis via alkiviadis.1961 on Inoreader http://ift.tt/2jEh3Lt